Professor of Health Economics, University of Manchester, UK
Katherine was awarded a personal Chair in Health Economics at The University of Manchester in August 2010.
She has over 16 years experience working as an academic health economist with different clinical research groups (pharmacy, psychiatry, genetics). Four years ago, Katherine joined the Health Sciences - Methodology Group, which allowed her to develop applied and methodological grants.
In 2007, she was awarded an RCUK Academic Fellowship to focus on the evaluation and valuation of genetic technologies including pharmacogenetic tests. She has expertise in the use of qualitative and quantitative methods to value and evaluate health care services, which forms the basis for the methodological and applied work in her Fellowship.
Ongoing and recent projects include: identifying and costing pathways of care for people with inherited ataxia; building an economic model to identify the most appropriate interval for breast cancer screening; preliminary economic evaluation of high-throughput whole genome sequencing technologies and economic evaluations of pharmacogenetic testing.
Recent examples of my work in stratified medicine include a prospective randomised trial and economic evaluation of TPMT testing for azathioprine and two health technology assessments of CYP2D6 testing for (1) patients treated with antipsychotics and (2) women with breast cancer treated with tamoxifen.